July 24 (Reuters) - Biogen and Sage

Therapeutics ( SAGE ) do not plan to conduct further studies for

their neurological disorder drug after it failed in a mid-stage

trial, the drugmakers said on Wednesday.

The experimental drug, SAGE-324, was being studied as a

treatment for essential tremor, a disorder that causes

uncontrollable shaking of the hands, arms and other body parts.

The drug failed to show statistically significant

dose-response relationship, as measured on a scale, for upper

limb tremor.

The companies said they were planning the next steps, if

any, to study the drug in other potential conditions.